BCSH Guidelines eBook

This content is coming soon.

Key recommendations
	Diagnosis
	Treatment
	Acute promyelocytic leukaemia
	Pregnancy
	Transplantation
1. Introduction
2. Methods
3. Classification of acute myeloid leukaemia
	Minimum laboratory requirements for the diagnosis of AML
4. Prognostic Factors
5. Appropriate setting for the management of acute myeloid leukaemia
	5.1. Patient Support
6. Treatment of acute myeloid leukaemia
	6.1. General measures and supportive care
	6.1.2. Hyperleucocytosis
	6.1.3. Prevention of tumour lysis syndrome
	Recommendation
	6.1.4. Red cell transfusion support
	6.1.5. Platelet support
	6.1.6. Granulocyte transfusions
	6.1.7. Antibiotic and anti-infective therapy
	6.1.8. Bacterial infection
	Recommendation
	6.1.9. Fungal infection
	6.1.10. Growth factors
	Recommendations
	6.2. Treatment of younger adult patients
	6.2.1. Induction therapy
	6.2.2. Addition of other drugs
	Recommendations
	6.2.3. Postremission therapy
	6.2.4. Maintenance therapy
	6.3. Management of AML in patients who are pregnant
	Recommendations
	6.4. Management of extramedullary disease
	Recommendation
	6.5. Management of central nervous system disease
7. Acute promyelocytic leukaemia
	7.1. Diagnosis of APL
	7.2. Clinical management
	7.2.1. Induction
	7.2.2. Supportive care
	7.2.3. Consolidation
	7.4. Management of APL patients at high risk of relapse
	7.5. Management of relapse
	7.5. Role of molecular monitoring
	Recommendations
8. Management of relapsed AML
9. Transplantation in AML
	9.1. Transplantation in relapsed and refractory disease
	9.2. Reduced intensity conditioning allografts
	9.3. Haplo-identical transplants
	9.4. T-cell depletion
	9.5. Quality of life issues
	Recommendations
10. Acute myeloid leukaemia in the elderly
	10.1. Standard chemotherapy
	Recommendations
	10.2. Non-intensive (palliative) chemotherapy
	Recommendations
11. Conclusions
Disclaimer
Appendix 1
References